PapersPMID:34815460
Effects of prenatal oral L-arginine on birth outcomes: a meta-analysis.
- findings
- 2
- compound
- 1
- endpoints
- 2
L-arginine- Study, every finding
- meta-analysis
What moved
How to read these marks →“In comparison to controls, the oral l-arginine groups showed significantly increased mean birthweight and gestational age (n = 8 and 5, respectively) in the total population.”
- Interests
- Industry funded
- Dose studied
- oral L-arginine 3 to 14 g/day, pooled; one trial gave 6.6 g/day with vitamins against vitamins alone
- Population
- Pregnant women in pooled randomised trials: at high risk of pre-eclampsia or with pre-eclampsia, gestational or mild chronic hypertension, with IUGR foetuses, or with threatened pre-term labour; controls received placebo, vitamins or no supplement
“In comparison to controls, the oral l-arginine groups showed significantly reduced risks of IUGR neonates, pre-term birth and respiratory distress syndrome (n = 7, 3 and 3, respectively) in the total population.”
- Interests
- Industry funded
- Dose studied
- oral L-arginine 3 to 6.6 g/day, pooled; one trial gave 6.6 g/day with vitamins against vitamins alone
- Population
- Pregnant women in pooled randomised trials with high risk of pre-eclampsia, or mild chronic hypertension; three studies, controls placebo or vitamins
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Pregnant women (singleton) at high risk of pre-eclampsia, or with pre-eclampsia, gestational or mild chronic hypertension, IUGR or threatened pre-term labour; 10 articles, 45 studies, 5763 mother-neonate pairs; oral L-arginine
- Participants
- 5,763
- Comparator
- an active treatment / placebo
- Duration
- not reported
- Endpoints measured
- 13
- Declined
- this platform holds no node for the endpoint